drugset / Trial / NCT05441267

A Study of Cardiovascular Events iN Diabetes Plus

NCT05441267

Phase 4 Active not recruiting 21296 enrolled University of Oxford Novo Nordisk A/S · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

ASCEND PLUS is testing whether, for people with type 2 diabetes who have not previously had a heart attack or stroke, regularly taking a tablet called semaglutide can safely help to reduce heart attacks, strokes, mini-strokes, the need for any procedures to unblock or bypass an artery to their heart, and the chance of dying because of vascular problems.

Timeline

Start
2023-03-13
Primary completion
2028-08-17
Completion
2048-08-17

Drugs

EvaluationDrugModalityDoseRoute
Comparator Semaglutide Peptide 14 mg Oral